Magnus Tobiasson

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: BLOOD. 2024;143(11):953-966

Identification and surveillance of rare relapse-initiating stem cells during complete remission after transplantation.

Dimitriou M; Mortera-Blanco T; Tobiasson M; Mazzi S; Lehander M; Högstrand K; Karimi M; Walldin G; Jansson M; Vonlanthen S; Ljungman P; Langemeijer S; Yoshizato T; Hellström-Lindberg E; Woll PS; Jacobsen SEW
Journal article: BLOOD. 2023;142:6039

New Assay Technology and Utility of Peripheral Blood Vs Bone Marrow for Molecular MRD in AML and MDS

Tobiasson M; Bosaeus L; Cavelier L; Chen L
Journal article: BLOOD. 2023;142:4587

Somatic Mutations and DNA Hypermethylation at Enhancers and Promoters Identify Distinct Subtypes within Lower-Risk Myelodysplastic Syndromes

Rombaut D; Tekath T; Sandmann S; Crouch S; De Graaf AO; Kosmider O; Tobiasson M; Lennartsson A; Van der Reijden BA; Park S; D'Aveni M; Slama B; Clappier E; Fenaux P; Ades L; De Loosdrecht AAV; Mc Langemeijer S; Symeonidis AS; Cermak J; Preudhomme C; Savic A; Germing U; Stauder R; Bowen DT; Van Marrewijk CJ; Bernard E; Smith A; Painter D; De Witte TJM; Lindberg EH; Varghese J; Dugas M; Martens JHA; Malcovati L; Jansen JH; Fontenay M
Journal article: BLOOD. 2023;142:1862

UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes

Sirenko M; Bernard E; Creignou M; Domenico D; Farina A; Ossa JEA; Kosmider O; Hasserjian R; Jadersten M; Germing U; Sanz G; van de Loosdrecht AA; Gurnari C; Follo MY; Thol F; Zamora L; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Ogawa S; Fontenay M; Jansen JH; Cervera J; Ebert BL; Bejar R; Greenberg PL; Gattermann N; Malcovati L; Cazzola M; Beck DB; Lindberg EH; Papaemmanuil E
Journal article: BLOOD. 2023;142:997

Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications

Bernard E; Hasserjian R; Greenberg PL; Ossa JEA; Creignou M; Nannya Y; Tuechler H; Medina-Martinez JS; Levine MF; Jadersten M; Germing U; Sanz G; van de Loosdrecht AA; Kosmider O; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Sirenko M; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Gattermann N; Ebert BL; Bejar R; Malcovati L; Cazzola M; Ogawa S; Lindberg EH; Papaemmanuil E
Article: CLINICAL CANCER RESEARCH. 2023;29(20):4256-4267

Integrated Genomic and Transcriptomic Analysis Improves Disease Classification and Risk Stratification of MDS with Ring Sideroblasts.

Todisco G; Creignou M; Bernard E; Björklund A-C; Moura PL; Tesi B; Mortera-Blanco T; Sander B; Jansson M; Walldin G; Barbosa I; Reinsbach SE; Hofman IJ; Nilsson C; Yoshizato T; Dimitriou M; Chang D; Olafsdottir S; Venckute Larsson S; Tobiasson M; Malcovati L; Woll P; Jacobsen SEW; Papaemmanuil E; Hellström-Lindberg E
Journal article: HEMASPHERE. 2023;7(Suppl):e790629d

P506: CLINICAL VALIDATION OF THE NORDIC GUIDELINES FOR GERMLINE TESTING IN MYELOID NEOPLASMS: RESULTS FROM A MULTI‐CENTER PROSPECTIVE COHORT STUDY

Tesi B; Eriksson A; Baskin B; Lazarevic V; Deneberg S; Höglund M; Fogelstrand L; Ungerstedt J; Pandzic T; Tobiasson M; Garelius HG; Kuchinskaya E; Persson F; Ågerstam H; Uggla B; Hallböök H; Fioretos T; Thuresson A; Lehmann S; Ladenvall C; Barbany G; Vennström L; Ejerblad E; Cavelier L; Cammenga J; Jädersten M; Lindberg EH; Baliakas P
Article: BLOOD ADVANCES. 2023;7(14):3624-3636

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.

Nannya Y; Tobiasson M; Sato S; Bernard E; Ohtake S; Takeda J; Creignou M; Zhao L; Kusakabe M; Shibata Y; Nakamura N; Watanabe M; Hiramoto N; Shiozawa Y; Shiraishi Y; Tanaka H; Yoshida K; Kakiuchi N; Makishima H; Nakagawa M; Usuki K; Watanabe M; Imada K; Handa H; Taguchi M; Kiguchi T; Ohyashiki K; Ishikawa T; Takaori-Kondo A; Tsurumi H; Kasahara S; Chiba S; Naoe T; Miyano S; Papaemanuil E; Miyazaki Y; Hellström-Lindberg E; Ogawa S
Article: BLOOD. 2023;142(1):73-89

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.

Dolinska M; Cai H; Månsson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson A-S; Deneberg S; Söderlund S; Jädersten M; Ungerstedt J; Tobiasson M; Östman A; Mustjoki S; Stenke L; Le Blanc K; Hellström-Lindberg E; Lehmann S; Ekblom M; Olsson-Strömberg U; Sigvardsson M; Qian H
Journal article: LEUKEMIA RESEARCH. 2023;128:107119

EARLY TRANSFUSION PATTERNS PREDICT OUTCOMES INDEPENDENTLY OF IPSS-M SCORE IN MYELODYSPLASTIC SYNDROMES

Creignou M; Bernard E; Crowther M; Tranberg A; Todisco G; Moura P; Ejerblad E; Nilsson L; Garelius H; Antunovic P; Lorenz F; Rasmussen B; Walldin G; Mortera-Blanco T; Jansson M; Tobiasson M; Edgren G; Jadersten M; Papaemmanuil E; Hellstrom-Lindberg E
Article: LAKARTIDNINGEN. 2022;119:22024

[Two cases of VEXAS syndrome].

Gunnarsson K; Vivar Pomiano N; Tesi B; Tobiasson M; Creignou M; Ungerstedt J
Article: NEJM EVID. 2022;1(7):evidoa2200008

Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

Bernard E; Tuechler H; Greenberg PL; Hasserjian RP; Arango Ossa JE; Nannya Y; Devlin SM; Creignou M; Pinel P; Monnier L; Gundem G; Medina-Martinez JS; Domenico D; Jädersten M; Germing U; Sanz G; van de Loosdrecht AA; Kosmider O; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Takaori-Kondo A; Ishikawa T; Chiba S; Kasahara S; Miyazaki Y; Viale A; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Solé F; Platzbecker U; Heuser M; Valent P; Ohyashiki K; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Gattermann N; Ebert BL; Bejar R; Malcovati L; Cazzola M; Ogawa S; Hellström-Lindberg E; Papaemmanuil E
Journal article: HEMASPHERE. 2022;6:68-69

S167: PREDICTION OF RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING INDIVIDUALIZED MEASURABLE RESIDUAL DISEASE MARKERS; THE PROSPECTIVE NORDIC STUDY NMDSG14B

Tobiasson M; Pandzic T; Illman J; Nilsson L; Weström S; Sollander K; Ejerblad E; Kittang AO; Olesen G; Werlenius O; Björklund A; Wiggh J; lindholm C; Lorentz F; Rasmussen B; Cammenga J; Weber D; Grönnås D; Dimitriou M; Kytölä S; Walldin G; Ljungman P; Groenbeck K; Mielke S; Jacobsen SE; Ebeling F; Cavelier L; Friis LS; Dybedal I; Hellström‐Lindberg E
Article: BONE MARROW TRANSPLANTATION. 2022;57(4):598-606

Failure to reach hematopoietic allogenic stem cell transplantation in patients with myelodysplastic syndromes planned for transplantation: a population-based study.

Lindholm C; Olofsson E; Creignou M; Nilsson L; Garelius HG; Cammenga J; Ljungman P; Ejerblad E; Tobiasson M
Article: JOURNAL OF MOLECULAR DIAGNOSTICS. 2021;23(3):347-357

Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data.

Sandmann S; de Graaf AO; Tobiasson M; Kosmider O; Abáigar M; Clappier E; Gallì A; van der Reijden BA; Malcovati L; Fenaux P; Díez-Campelo M; Fontenay M; Hellström-Lindberg E; Jansen JH; Dugas M
Journal article: BLOOD. 2020;136:5-6

Prediction of Relapse after Allogeneic Stem Cell Transplantation Using Individualized Minimal Residual Markers; The Prospective Nordic Study NMDSG14B

Tobiasson M; Pandzic T; Illman J; Nilsson L; Westrom S; Olsson D; Ejerblad E; Kittang AO; Olesen G; Werlenius O; Bjorklund AT; Lorentz F; Rasmussen BEH; Cammenga J; Weber D; Dimitriou M; Kytola S; Walldin G; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Friis LS; Dybedal I; Lindberg EH
Journal article: BLOOD. 2020;136(Supplement 1):38-40

Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms

Makishima H; Nannya Y; Takeda J; Momozawa Y; Saiki R; Yoshizato T; Atsuta Y; Iijima-Yamashita Y; Yoshida K; Shiraishi Y; Nagata Y; Shiozawa Y; Onizuka M; Chiba K; Tanaka H; Kakiuchi N; Ochi Y; Ueno H; Itonaga H; Kanda Y; Sanada M; Kon A; Miyazaki Y; Horibe K; Creignou M; Tobiasson M; Tsurumi H; Kasahara S; Polprasert C; Lindberg EH; Takaori AK; Kiguchi T; Cazzola M; Matsuda F; Ohyashiki K; Maciejewski JP; Haferlach T; Kamatani Y; Kubo M; Miyano S; Ogawa S
Journal article: BLOOD. 2020;136(Supplement 1):12-13

Post-Treatment Clone Size Predicts Survival Independently of IPSS-R and Response after Azacitidine Therapy for MDS.

Nannya Y; Tobiasson M; Sato S; Bernard E; Creignou M; Zhao L; Takeda J; Shiraishi Y; Chiba K; Tanaka H; Tsurumi H; Kasahara S; Taguchi M; Takaori AK; Ohyashiki K; Makishima H; Yoshida K; Naoe T; Miyano S; Miyazaki Y; Papaemmanuil E; Lindberg EH; Ogawa S
Journal article: BLOOD. 2020;136(Supplement 1):29

Mutation Profiles Identify Distinct Clusters of Lower Risk Myelodysplastic Syndromes with Unique Clinical and Biological Features and Clinical Endpoints

Malcovati L; Crouch S; De Graaf AO; Sandmann S; Tobiasson M; Kosmider O; van der Reijden BA; Painter D; Van de Loosdrecht AA; Symeonidis A; Cermak J; Clappier E; Preudhomme C; Stauder R; Mittelman M; Germing U; Bowen D; Fenaux P; Van Marrewijk C; Smith A; Dugas M; Lindberg EH; de Witte TM; Fontenay M; Jansen J
Article: NATURE MEDICINE. 2020;26(10):1549-1556

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Elias HK; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
Article: LEUKEMIA. 2019;33(2):522-527

Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes.

Rydén J; Edgren G; Karimi M; Walldin G; Tobiasson M; Wikman A; Hellström-Lindberg E; Höglund P
Article: ONCOLOGIST. 2018;23(2):159-170

Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.

Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
Article: BLOOD. 2017;130(7):881-890

SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells.

Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellström-Lindberg E
Article: CELL REPORTS. 2017;20(3):572-585

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.

Unnikrishnan A; Papaemmanuil E; Beck D; Deshpande NP; Verma A; Kumari A; Woll PS; Richards LA; Knezevic K; Chandrakanthan V; Thoms JAI; Tursky ML; Huang Y; Ali Z; Olivier J; Galbraith S; Kulasekararaj AG; Tobiasson M; Karimi M; Pellagatti A; Wilson SR; Lindeman R; Young B; Ramakrishna R; Arthur C; Stark R; Crispin P; Curnow J; Warburton P; Roncolato F; Boultwood J; Lynch K; Jacobsen SEW; Mufti GJ; Hellstrom-Lindberg E; Wilkins MR; MacKenzie KL; Wong JWH; Campbell PJ; Pimanda JE
Article: ONCOTARGET. 2017;8(17):28812-28825

Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.

Tobiasson M; Abdulkadir H; Lennartsson A; Katayama S; Marabita F; De Paepe A; Karimi M; Krjutskov K; Einarsdottir E; Grövdal M; Jansson M; Ben Azenkoud A; Corddedu L; Lehmann S; Ekwall K; Kere J; Hellström-Lindberg E; Ungerstedt J
Article: ONCOTARGET. 2016;7(16):22103-22115

Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.

Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jädersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellström-Lindberg E
Article: CANCER CELL. 2014;25(6):794-808

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Woll PS; Kjällquist U; Chowdhury O; Doolittle H; Wedge DC; Thongjuea S; Erlandsson R; Ngara M; Anderson K; Deng Q; Mead AJ; Stenson L; Giustacchini A; Duarte S; Giannoulatou E; Taylor S; Karimi M; Scharenberg C; Mortera-Blanco T; Macaulay IC; Clark S-A; Dybedal I; Josefsen D; Fenaux P; Hokland P; Holm MS; Cazzola M; Malcovati L; Tauro S; Bowen D; Boultwood J; Pellagatti A; Pimanda JE; Unnikrishnan A; Vyas P; Göhring G; Schlegelberger B; Tobiasson M; Kvalheim G; Constantinescu SN; Nerlov C; Nilsson L; Campbell PJ; Sandberg R; Papaemmanuil E; Hellström-Lindberg E; Linnarsson S; Jacobsen SEW
Article: BLOOD CANCER JOURNAL. 2014;4(3):e189

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial.

Tobiasson M; Dybedahl I; Holm MS; Karimi M; Brandefors L; Garelius H; Grövdal M; Högh-Dufva I; Grønbæk K; Jansson M; Marcher C; Nilsson L; Kittang AO; Porwit A; Saft L; Möllgård L; Hellström-Lindberg E
Journal article: BLOOD. 2013;122(21):4195

Diverse Genetic Lesions In Myelodysplastic Syndromes Originate Exclusively In Rare MDS Stem Cells

Woll P; Kjällquist U; Chowdhury O; Erlandsson R; Doolittle H; Ngara M; Anderson K; Giannoulatou E; Taylor S; Deng Q; Mead AJ; Scharenberg C; Mortera-Blanco T; Macaulay IC; Clark S-A; Josefsen D; Kvalheim G; Göhring G; Schlegelberger B; Tobiasson M; Holm MS; Hokland P; Fenaux P; Nerlov C; Dybedal I; Nilsson L; Sandberg R; Hellström-Lindberg E; Linnarsson S; Jacobsen SEW
Journal article: BLOOD. 2011;118(21):3798

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Tobiasson M; Brandefors L; Dybedal I; Garelius H; Grövdal M; Dufva IH; Kjeldsen L; Nilsson L; Kittang AO; Porwit A; Saft L; Holm MS; Möllgård L; Hellström-Lindberg E
Article: BONE MARROW TRANSPLANTATION. 2011;46(5):719-726

Early detection of relapse in patients with myelodysplastic syndrome after allo-SCT.

Tobiasson M; Olsson R; Hellström-Lindberg E; Mattsson J
Article: MEDICAL ONCOLOGY. 2010;27(1):105-107

High prevalence of restless legs syndrome among patients with polycytemia vera treated with venesectio.

Tobiasson M; Alyass B; Söderlund S; Birgegård G
Visa fler

Alla övriga publikationer

Editorial comment: HAEMATOLOGICA. 2023;108(7):1968-1971

Omalizumab alleviates pruritus in myeloproliferative neoplasms.

Landtblom AR; Ungerstedt J; Hedlund A; Tobiasson M; Deneberg S; Jädersten M
Conference publication: LEUKEMIA RESEARCH. 2023;128:107124

POST-AZACITIDINE CLONE SIZE PREDICTS LONG-TERM OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND RELATED MYELOID NEOPLASMS

Nannya Y; Tobiasson M; Sato S; Bernard E; Ohtake S; Takeda J; Creignou M; Kusakabe M; Shibata Y; Nakamura N; Watanabe M; Hiramoto N; Shiozawa Y; Shiraishi Y; Tanaka H; Yoshida K; Kakicuchi N; Makishima H; Nakagawa M; Usuki K; Watanabe M; Imada K; Handa H; Taguchi M; Kiguchi T; Ohyashiki K; Ishikawa T; Takaori A; Tsurumi H; Kasahara S; Chiba S; Naoe T; Miyano S; Papaemmanuil E; Miyazaki Y; Hellstrom-Lindberg E; Ogawa S
Conference publication: LEUKEMIA RESEARCH. 2023;128:107146

GENOMIC CLASSIFICATION OF MYELODYSPLASTIC SYNDROMES

Bernard E; Hasserjian R; Greenberg P; Ossa JA; Creignou M; Nannya Y; Tuechler H; Medina-Martinez J; Levine M; Jadersten M; Germing U; Sanz G; Van De Loosdrecht A; Kosmider O; Follo M; Thol F; Zamora L; Pinheiro R; Pellagatti A; Elias H; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta M; Fenaux P; Belickova M; Savona M; Klimek V; Santos F; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen J; Cervera-Zamora J; Gattermann N; Ebert B; Bejar R; Malcovati L; Cazzola M; Ogawa S; Hellstrom-Lindberg E; Papaemmanuil E
Conference publication: LEUKEMIA RESEARCH. 2023;128:107227

COMPARISON OF MRD-MARKERS USING MUTATION-SPECIFIC DDPCR IN BONE MARROWAND PERIPHERAL BLOOD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MDS

Lindholm C; Tobiasson M; Pandzic T; Illman J; Nilsson L; Westrom S; Ejerblad E; Olesen G; Bjorklund A; Kittang AO; Werlenius O; Wiggh J; Lorentz F; Rasmussen B; Cammenga J; Weber D; Moen AE; Lundstrom LY; Von Bahr L; Dimitriou M; Kytola S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SE; Ebeling F; Cavelier L; Friis LS; Dybedal I; Hellstrom-Lindberg E
Preprint: BIORXIV. 2023

Dysregulated expression of Hoxa1 isoforms in hematopoietic stem and progenitor cells causes myelodysplastic syndromes

Tan S; Joseph C; Chalk AM; Hendy J; Fabb S; Schleibs K; Lee SC; Tjin G; Grace CS; Madugalle V; Smeets MF; Maluenda AC; Rice KL; Baker EK; Nandurkar H; Slape CI; Parker MW; Unnikrishnan A; Mufti GJ; Tobiasson M; Hellstrom-Lindberg E; Pimanda JE; Gudas LJ; Holien JK; Walkley CR; Wall M; Purton LE
Conference publication: BLOOD. 2022;140:9785-9788

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Sirenko M; Bernard E; Beck DB; Creignou M; Domenico D; Farina A; Arango JE; Kosmider O; Hasserjian RP; Jadersten M; Germing U; Sanz G; van de Loosdrecht AA; Follo MY; Thol FR; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; de Souza Santos FP; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Ogawa S; Fontenay M; Jansen JH; Cervera J; Ebert BL; Bejar R; Greenberg PL; Gattermann N; Malcovati L; Cazzola M; Hellstrom-Lindberg E; Papaemmanuil E
Meeting abstract: BLOOD. 2022;140:6968-6970

Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes

Creignou M; Bernard E; Crowther M; Tranberg A; Ejerblad E; Nilsson L; Garelius H; Antunovic P; Rasmussen BEH; Lorenz F; Todisco G; Walldin G; Mortera-Blanco T; Jansson M; Tobiasson M; Edgren G; Jadersten M; Papaemmanuil E; Hellstrom-Lindberg E
Letter: BLOOD ADVANCES. 2022;6(16):4705-4709

The extent of residual WT HSPCs is associated with the degree of anemia in patients with SF3B1-mutated MDS-RS.

Hofman IJF; Mortera-Blanco T; Moura PL; Vestlund J; Larsson SV; Elvarsdottir EM; Walldin G; Tobiasson M; Sander B; Dimitriou M; Jacobsen S-EW; Woll PS; Jädersten M; Hellström-Lindberg E
Letter: LEUKEMIA. 2022;36(5):1436-1439

"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".

Rasmussen B; Göhring G; Bernard E; Nilsson L; Tobiasson M; Jädersten M; Garelius H; Dybedal I; Grønbaek K; Ejerblad E; Lorenz F; Flogegård M; Marcher CW; Öster Fernström A; Cavelier L; Papaemmanuil E; Ebeling F; Kittang AO; Nørgaard JM; Saft L; Möllgård L; Hellström-Lindberg E
Letter: LEUKEMIA & LYMPHOMA. 2022;63(3):755-758

Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.

Jädersten M; Boriskina K; Lindholm C; Weström S; Cavelier L; Hellström-Lindberg E; Mielke S; Tobiasson M
Preprint: RESEARCH SQUARE. 2021

Post-azacitidine clone size predicts long-term clinical outcome of patients with myelodysplastic syndromes and related myeloid neoplasms

Ogawa S; Tobiasson M; Sato S; Bernard E; Ohtake S; Takeda J; Creignou M; Zhao L; Kusakabe M; Shibata Y; Nakamura N; Watanabe M; Hiramoto N; Shiozawa Y; Shiraishi Y; Tanaka H; Yoshida K; Kakiuchi N; Makishima H; Nakagawa M; Usuki K; Watanabe M; Imada K; Handa H; Taguchi M; Kiguchi T; Ohyashiki K; Ishikawa T; Takaori-Kondo A; Tsurumi H; Kasahara S; Chiba S; Naoe T; Miyano S; Papaemmanuil E; Miyazaki Y; Hellstrom-Lindberg E
Corrigendum: NATURE MEDICINE. 2021;27(5):927

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Elias HK; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
Letter: BLOOD. 2021;137(9):1260-1263

Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder.

Klimkowska M; Nannya Y; Gran C; Månsson R; Douagi I; Ogawa S; Nahi H; Tobiasson M
Corrigendum: NATURE MEDICINE. 2021;27(3):562

Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.

Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Solé F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
Conference publication: LEUKEMIA RESEARCH. 2021;108:S7-S8

MYELOID NEOPLASMS WITH GERMLINE AND SOMATIC DDX41 MUTATIONS

Makishima H; Nannya Y; Momozawa Y; Gurnari C; Kulasekararaj A; Yoshizato T; Takeda J; Atsuta Y; Shiozawa Y; Iijima-Yamashita Y; Saiki R; Yoshida K; Shiraishi Y; Nagata Y; Onizuka M; Nakagawa M; Itonaga H; Kanda Y; Miyazaki Y; Sanada M; Tsurumi H; Kasahara S; Kondo-Takaori A; Ohyashiki K; Kiguchi T; Matsuda F; Jansen J; Papaemmanuil E; Creignou M; Tobiasson M; Hellstrom-Lindberg E; Polprasert C; Malcovati L; Cazzola M; Haferlach T; Maciejewski J; Kamatani Y; Miyano S; Ogawa S
Review: HAEMATOLOGICA. 2020;105(7):1765-1779

Myelodysplastic syndromes: moving towards personalized management.

Hellström-Lindberg E; Tobiasson M; Greenberg P
Preprint: BIORXIV. 2019

Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Sole F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jädersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellström-Lindberg E; Ogawa S; Papaemmanuil E
Conference publication: BLOOD. 2019;134:675

TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Bernard E; Nannya Y; Yoshizato T; Hasserjian RP; Saiki R; Shiozawa Y; Devlin SM; Tuechler H; Sarian A; Malcovati L; Sole F; Haase D; Creignou M; Levine M; Germing U; Cargo C; Zhang Y; Medina J; Ossa JEA; Schanz J; van de Loosdrecht A; Jadersten M; Bennett JM; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Klimek VM; Savona MR; Belickova M; Ganster C; Ades L; Della Porta MG; Smith A; Werner Y; Patel MA; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton K; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Lindberg EH; Ogawa S; Papaemmanuil E
Conference publication: BLOOD. 2019;134:4246

Molecular Characteristics That Predict Response to Azacitidine Therapy

Nannya Y; Tobiasson M; Bernard E; Sato S; Creignou M; Takeda J; Zhao L; Shiraishi Y; Chiba K; Tanaka H; Tsurumi H; Kasahara S; Taguchi M; Takaori AK; Ohyashiki K; Makishima H; Yoshida K; Naoe T; Miyazaki Y; Miyano S; Papaemmanuil E; Lindberg EH; Ogawa S
Letter: LEUKEMIA & LYMPHOMA. 2019;60(13):3316-3319

Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission.

Tobiasson M; Pandzic T; Cavelier L; Sander B; Wahlin BE
Review: JOURNAL OF INTERNAL MEDICINE. 2019;286(1):41-62

Treatment of myelodysplastic syndrome in the era of next-generation sequencing.

Tobiasson M; Kittang AO
Conference publication: HAEMATOLOGICA. 2016;101:70

MODEST EPIGENETIC EFFECT OF AZACITIDINE IN GENOME-WIDE MAPPING OF DNA METHYLATION, H3K9ME3, H3K18AC AND GENE EXPRESSION IN MDS PROGENITORS

Tobiasson M; Ali HA; Lennartsson A; Katayama S; Marabita F; Karimi M; Khrjutskhov K; Einarsdottir E; Jansson M; Ben Azenkoud A; Ekwall K; Kere J; Hellstrom-Lindberg E; Ungerstedt J
Conference publication: HAEMATOLOGICA. 2016;101:157-158

INTEGRATIVE GENOMICS IDENTIFIES THE MOLECULAR BASIS OF RESISTANCE TO AZACITIDINE THERAPY IN MYELODYSPLASTIC SYNDROMES

Unnikrishnan A; Papaemmanuil E; Beck D; Verma A; Kumari A; Woll P; Richards L; Knezevic K; Chandrakanthan V; Thoms J; Tursky M; Huang Y; Ali Z; Olivier J; Galbraith S; Kulasekararaj A; Tobiasson M; Karimi M; Pellagatti A; Wilson S; Lindeman R; Young B; Ramakrishna R; Arthur C; Stark R; Crispin P; Curnow J; Warburton P; Roncolato F; Boultwood J; Lynch K; Jacobsen S; Mufti G; Hellstrom-Lindberg E; MacKenzie K; Wong J; Campbell P; Pimanda J
Conference publication: BLOOD. 2015;126(23):710

An Integrative Genomics Approach Uncovers the Basis of Resistance to AZA Therapy in MDS and CMML

Unnikrishnan A; Papaemmanuil E; Beck D; Verma A; Kumari A; Richards LA; Knezevic K; Chandrakanthan V; Thoms JAI; Tursky ML; Huang Y; Galbraith S; Kulasekararaj AG; Tobiasson M; Woll PS; Pellagatti A; Wilson SR; Lindeman R; Boultwood J; Lynch K; Jacobsen SE; Mufti GJ; Hellstrom-Lindberg E; Mackenzie KL; Wong JWH; Campbell PJ; Pimanda JE
Conference publication: BLOOD. 2015;126(23):2839

Mutations in Histone Modulators Are Associated with Prolonged Survival during Azacitidine Therapy

Tobiasson M; MeLornan D; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jadersten M; Lindberg G; Abdulkadir H; Kulasekararaj AG; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellstrom-Lindberg E
Meeting abstract: LEUKEMIA RESEARCH. 2015;39:S69

IN VITRO AZACITIDINE CULTURE INDUCES DNA DEMETHYLATION AND INCREASED MRNA-LEVELS IN PRIMARY MDS PROGENITOR CELLS

Abdulkadir H; Tobiasson M; Lennartsson A; Katayama S; Marabita F; Karimi M; Qu Y; Einarsdottir E; Govdal M; Jansson M; Ben Azenkoud A; Lehmann S; Ekwall K; Kere J; Hellstom-Lindberg E; Ungerstedt J
Corrigendum: CANCER CELL. 2015;27(4):603-605

Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo (vol 25, pg 794, 2014)

Woll PS; Kjaellquist U; Chowdhury O; Doolittle H; Wedge DC; Thongjuea S; Erlandsson R; Ngara M; Anderson K; Deng Q; Mead AJ; Stenson L; Giustacchini A; Duarte S; Giannoulatou E; Taylor S; Karimi M; Scharenberg C; Mortera-Blanco T; Macaulay IC; Clark S-A; Dybedal I; Josefsen D; Fenaux P; Hokland P; Holm MS; Cazzola M; Malcovati L; Tauro S; Bowen D; Boultwood J; Pellagatti A; Pimanda JE; Unnikrishnan A; Vyas P; Goehring G; Schlegelberger B; Tobiasson M; Kvalheim G; Constantinescu SN; Nerlov C; Nilsson L; Campbell PJ; Sandberg R; Papaemmanuil E; Hellstroem-Lindberg E; Linnarsson S; Jacobsen SEW
Meeting abstract: LEUKEMIA RESEARCH. 2015;39:S153

DEVELOPMENT AND IMPLEMENTATION OF A NEW BIOBANK SYSTEM

Jansson M; Walldin G; Ben Azenkoud A; Dimitriou M; Karimi M; Tobiasson M; Jadersten M; Tapia J; Lindberg EH
KI thesis / dissertation: 2015

Clinical and molecular effects of azacitidine in the myelodysplastic syndromes

Tobiasson, Magnus
Conference publication: BLOOD. 2014;124(21):4601

Identification of a Prognostic Gene Expression Signature for AZA Response in MDS and CMML Patients

Unnikrishnan A; Beck D; Verma A; Richards LA; Thoms JAI; Kumari A; Galbraith S; Kulasekararaj A; Tobiasson M; Woll PS; Pellagatti A; Papaemmanuil E; Wilson SR; Lindeman R; Campbell PJ; Boultwood J; Lynch K; Jacobsen SEW; Mufti GJ; Hellstrom-Lindberg E; MacKenzie KL; Wong JWH; Pimanda JE
Conference publication: BLOOD. 2014;124(21):4613

Mutations in Histone Modulators and HOXA5 Methylation Levels Affects Survival in Azacitidine Treated MDS Patients

Tobiasson M; Karimi M; Dimitriou M; Qu Y; Lennartsson A; Ali HA; Unnikrishnan A; Jadersten M; Jansson M; Ben Azenkoud A; Pimanda JE; Ekwall K; Ungerstedt J; Lehmann S; Hellstrom-Lindberg E
Corrigendum: CANCER CELL. 2014;25(6):861

Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo (vol 25, pg 794, 2014)

Woll PS; Kjaellquist U; Chowdhury O; Doolittle H; Wedge DC; Thongjuea S; Erlandsson R; Ngara M; Anderson K; Deng Q; Mead AJ; Stenson L; Giustacchini A; Duarte S; Giannoulatou E; Taylor S; Karimi M; Scharenberg C; Mortera-Blanco T; Macaulay IC; Clark S-A; Dybedal I; Josefsen D; Fenaux P; Hokland P; Holm MS; Cazzola M; Malcovati L; Tauro S; Bowen D; Boultwood J; Pellagatti A; Pimanda JE; Unnikrishnan A; Vyas P; Goehring G; Schlegelberger B; Tobiasson M; Kvalheim G; Constantinescu SN; Nerlov C; Nilsson L; Campbell PJ; Sandberg R; Papaemmanuil E; Hellstroem-Lindberg E; Linnarsson S; Jacobsen SEW
Letter: LEUKEMIA. 2014;28(2):411-413

Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation.

Grövdal M; Karimi M; Tobiasson M; Reinius L; Jansson M; Ekwall K; Ungerstedt J; Kere J; Greco D; Hellström-Lindberg E
Conference publication: BLOOD. 2012;120(21):2394

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine

Treppendahl MB; Tobiasson M; Aggerholm A; Karimi M; Silkjaer T; Friis LS; Andersen MK; Kjeldsen L; Holm MS; Hellstrom-Lindberg E; Gronbaek K
Conference publication: HAEMATOLOGICA. 2012;97:140-141

EVALUATION OF AZACITIDINE IN TRANSFUSION-DEPENDENT, EPO-REFRACTORY PATIENTS WITH LOWER-RISK MDS

Tobiasson M; Brandefors L; Dybedahl I; Garelius H; Grovdal M; Hogh-Dufva I; Kjeldsen L; Marcher C; Nilsson L; Kittang AO; Porwit A; Saft L; Holm MS; Mollgard L; Hellstrom-Lindberg E
Conference publication: BLOOD. 2011;118(21):1622-1623

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome

Tobiasson M; Brandefors L; Dybedal I; Garelius H; Grovdal M; Dufva IH; Kjeldsen L; Nilsson L; Kittang AO; Porwit A; Saft L; Holm MS; Mollgard L; Hellstrom-Lindberg E
Conference publication: BONE MARROW TRANSPLANTATION. 2009;43:S276-S277

Chimerism analysis as a predictor of relapse of myelodysplastic syndrome after allogeneic stem cell transplantation

Tobiasson M; Olsson R; Remberger M; Hellstrom-Lindberg E; Mattsson J
Visa fler

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2023-2026

Examina och utbildning

Docent, hematologi, Karolinska Institutet, 2022
Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2015

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI